Tomoyuki Mutoh

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 13

Top Topics

Interstitial Lung Disease

Rheumatoid Arthritis

Monoclonal Antibody

Systemic Lupus Erythematosus

Top Venues

Arthritis & rheumatology (Hoboken, N.J.)

Rheumatology international

The Journal of rheumatology

European journal of rheumatology

This page only lists publications with an associated author ORCID identifier.

Publications

Tomoyuki Mutoh, Sadanori Furudate, Mamoru Narita, Taichi Nagai, Shinji Taniuchi, Masataka Kudo, Hiroshi Fujii
Multiple punched-out ulcerations on the abdomen in anti-melanoma differentiation-associated gene 5 dermatomyositis. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Tomoyuki Mutoh, Masataka Kudo, Akira Tsukada
Ixekizumab for brodalumab-induced articular involvement in psoriatic arthritis: beyond IL-17A inhibition. Rheumatology international (2023)
Tomoyuki Mutoh, Ryoto Sasaki, Kazuhiro Sakamoto, Masataka Kudo
Hairy kidney in IgG4-related disease. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Tomoyuki Mutoh, Sadanori Furudate, Mamoru Narita, Taichi Nagai, Shinji Taniuchi, Masataka Kudo, Hiroshi Fujii
Multiple punched-out ulcerations on the abdomen in anti-melanoma differentiation-associated gene 5 dermatomyositis. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Tomoyuki Mutoh, Sadanori Furudate, Mamoru Narita, Taichi Nagai, Shinji Taniuchi, Masataka Kudo, Hiroshi Fujii
Multiple punched-out ulcerations on the abdomen in anti-melanoma differentiation-associated gene 5 dermatomyositis. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Tomoyuki Mutoh, Keiichi Ohashi, Taichi Nagai, Akira Sugiura, Masataka Kudo, Hiroshi Fujii
Upfront rituximab therapy for thrombotic thrombocytopenic purpura in systemic lupus erythematosus: a case-based review. Rheumatology international (2022)
Tomoyuki Mutoh, Mikihiro Takahashi, Taichi Nagai, Masataka Kudo
Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease? The Journal of rheumatology (2022)
Tomoyuki Mutoh, Taichi Nagai, Tsuyoshi Shirai, Soshi Okazaki, Hiroko Sato, Hiroshi Fujii
Predictive factors for retention of golimumab over a median 4-year duration in Japanese patients with rheumatoid arthritis in a real-world setting: A retrospective study and literature review. International journal of rheumatic diseases 25 (3) (2022)
Tomoyuki Mutoh, Tsuyoshi Shirai, Hiroko Sato, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae
Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review. Rheumatology international (2021)
Tomoyuki Mutoh, Tsuyoshi Shirai, Tomonori Ishii, Yuko Shirota, Fumiyoshi Fujishima, Fumiaki Takahashi, Yoichi Kakuta, Yoshitake Kanazawa, Atsushi Masamune, Yoshikatsu Saiki, Hideo Harigae, Hiroshi Fujii
Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis. Nature communications 11 (1) (2020)
Tomoyuki Mutoh, Yuko Shirota, Azusa Ito, Hiroshi Fujii, Tomonori Ishii, Toru Nakazawa, Hideo Harigae
One after another retinal involvement in lupus. European journal of rheumatology (2020)
Tomoyuki Mutoh, Tsuyoshi Shirai, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae
Insufficient Use of Corticosteroids without Immunosuppressants Results in Higher Relapse Rates in Takayasu Arteritis. The Journal of rheumatology 47 (2) (2019)
Tomoyuki Mutoh, Tomonori Ishii, Tsuyoshi Shirai, Kanae Akita, Yukiko Kamogawa, Yoko Fujita, Hiroko Sato, Yuko Shirota, Hiroshi Fujii, Hideo Harigae
Refractory Takayasu arteritis successfully treated with rituximab: case-based review. Rheumatology international 39 (11) (2019)